U.K. gatekeepers doubt the value of Millennium Crohn's med

The U.K.'s cost-effectiveness watchdog says it's not planning to recommend a new Crohn's disease treatment from Millennium Pharmaceuticals. The National Institute for Health and Care Excellence (NICE) cited uncertain evidence for the drug, Entyvio, and said it's unlikely it would be a good value for the National Health Service. The draft decision comes despite the Takeda unit's offer of a discount. Report

Suggested Articles

BMS' Opdivo and Yervoy only just won their first approval in previously untreated metastatic NSCLC, but the pair is already making it two.

Takeda’s Alunbrig has arrived in previously untreated, ALK-positive NSCLC. But there’s plenty of competition waiting to greet it at the door.

Sanofi and Regeneron's blockbuster Dupixent is eyeing an approval in eosinophilic esophagitis after cutting patients' difficulty breathing.